Cover Image
市場調查報告書

無聲的癌症的治療

Therapeutics for 'Silent' Cancers

出版商 BCC Research 商品編碼 324738
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
Back to Top
無聲的癌症的治療 Therapeutics for 'Silent' Cancers
出版日期: 2015年02月20日 內容資訊: 英文 123 Pages
簡介

全球無聲的癌症市場,2013年達到了85億美元,2014年達到了90億美元的市場規模。該市場預計從2014年到2019年以8.5%的年複合成長率發展,到2019年成長到約136億美元的規模。

本報告提供稱為無聲的癌症的8個癌症相關研究、全球無聲的癌症治療市場、技術的現況與展望的相關調查、全球市場趨勢的分析與年複合成長率預測、癌症的說明、現在可以利用的治療的評估,臨床開發中的新藥評估,以及整主要企業的簡介等彙。

第1章 簡介

第2章 摘要

第3章 概要

  • 癌症:全球展望
  • 增加嚴重的問題
  • 市場動態
  • 幾個主要的抗癌劑
    • 藥物分類
  • 無症狀性癌症
    • 暴露遺傳基因
    • 腫瘤標記

第4章 腦瘤

  • 原因、頻率及經過
  • 診斷
    • 影像檢查
    • MRI
    • 預後
    • 治療
    • 放射治療、神經毒性
    • 化療
  • 研究主要的發展
  • 市場

第5章 口腔、咽癌症

  • 原因、頻率及經過
  • 診斷
  • 治療
  • 喉癌症
  • 新的研究開發
  • 市場

第6章 食道癌症

  • 原因、頻率及經過
  • 診斷
  • 治療
  • 新的研究開發
    • 遺傳學
    • 篩檢、預防
    • 手術
    • 化療
    • 標靶藥物
  • 市場

第7章 肝臟癌症

  • 原因、頻率及經過
  • 診斷
  • 治療
  • 其他原發性肝癌症
  • 轉移癌
    • 病毒治療
  • 新的研究開發
  • 市場

第8章 腎臟癌症

  • 原因、頻率及經過
  • 診斷
  • 治療
  • 新的研究開發
    • 遺傳學
    • 對局部療法的新方法
    • 標靶治療
    • 免疫療法
    • 疫苗
    • 骨髓或幹細胞移植
  • 市場

第9章 胰臟癌症

  • 原因、頻率及經過
  • 診斷
  • 治療
  • 新的研究開發
  • 市場

第10章 脖子癌症

  • 原因、頻率及經過
  • 診斷
  • 治療
    • 預防:疫苗
    • 治療
  • 新的研究開發
    • IXEMPRA
    • ISA101 VACCINE
    • VELIPARIB
    • OLAPARIB
  • 市場

第11章 卵巢癌症

  • 原因、頻率及經過
  • 診斷
  • 治療
    • PACLITAXEL
    • CARBOPLATIN
    • DOXIL
    • TAXOTERE/DOCETAXEL
    • CISPLATIN
    • GEMZAR
    • HYCAMTIN
    • NAVELBINE
    • CARBOPLATIN
  • 卵巢癌症篩檢
    • CA125血液檢驗
    • 經陰道超音波檢驗
  • 新的研究開發
    • 風險因素、原因
    • 預防
    • 診斷
    • 治療
  • 市場

第12章 腫瘤標記

  • 篩檢與早期發現
  • 癌症的診斷
  • 監測
    • 復發的探勘
  • 發現在癌症本身的腫瘤標記
    • 未分化淋巴瘤激酶 (ALK)
    • BRAF
    • 表皮成長因素受體 (EGFR)
    • HER2 (或 HER2/NEU, ERBB-2, 或 EGFR2)
    • 荷爾蒙受體
    • KRAS
    • S-100
  • 腫瘤標記研究中的新方向性
    • 基因學
    • 蛋白質體學

第13章 企業簡介

第14章 附錄1:用語

圖表

目錄
Product Code: PHM169A

The global market for "silent" cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual growth rate (CAGR) of 8.5% from 2014 to 2019.

This report provides: An overview of the global markets and technologies for the therapeutics for "silent" cancers. Analyses of global market trends, with data from 2013, 2014, and projections of CAGRs through 2019. Descriptions of cancers, with incidence and prevalence data for all major national markets. Assessments of currently available therapies. Evaluation of new agents now in clinical development, with likely launch timetables and estimates of potential clinical value. Profiles of major players in the "silent" cancer therapeutics industry.

image1

REPORT SCOPE

SCOPE OF REPORT

The report discusses eight cancers described as "silent and deadly" because they are often undiagnosed until the diseases is advanced and difficult to treat. These cancers are brain, cervix, esophagus, mouth and larynx, ovary, pancreas, kidney, and lastly, liver. For each cancer, the cause, clinical course, diagnosis and treatment are described. Current drug therapy is outlined and new research activities are listed. The market is summarized and quantified for each cancer, with estimates of recent (2013) and current (2014) values for each cancer, and five-year projection to 2019. Geographically, the global market is given, with country analyses for the U.S., Japan, and five major Western European markets: Germany, France, Italy, Spain and the United Kingdom.

ANALYST'S CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the cancer marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR "SILENT" CANCERS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET SHARE FOR (%)

CHAPTER 3 OVERVIEW

  • CANCER: A GLOBAL PERSPECTIVE
  • GROWING PROBLEM
  • MARKET DYNAMICS
  • SOME LEADING ANTICANCER DRUGS
    • DRUG CATEGORIES
  • ASYMPTOMATIC CANCER
    • TELLTALE GENES
    • TUMOR MARKERS

CHAPTER 4 BRAIN CANCER

  • CAUSE, FREQUENCY AND COURSE
  • DIAGNOSIS
    • IMAGING TESTS
    • MRI
      • CT Scan
      • PET Scan 2
      • Cerebral Arteriogram
      • Lumbar Puncture or Spinal Tap
      • Myelogram
      • Tissue Sampling/Biopsy/Surgical Removal of a Tumor
    • PROGNOSIS
    • TREATMENT
    • RADIATION THERAPY AND NEUROTOXICITY
    • CHEMOTHERAPY
  • NEW DEVELOPMENTS IN RESEARCH
    • TABLE 1 COMPOUNDS IN CLINICAL DEVELOPMENT FOR BRAIN CANCER
    • RECENT RESEARCH REPORTS
  • MARKET
  • TABLE 2 GLOBAL AND U.S. BRAIN CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 3 BRAIN CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 4 BRAIN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

CHAPTER 5 CANCER OF THE MOUTH AND LARYNX

  • CAUSE, FREQUENCY AND COURSE
  • DIAGNOSIS
  • TREATMENT
  • LARYNGEAL CANCER
    • CAUSE, FREQUENCY AND COURSE
    • DIAGNOSIS
    • TREATMENT
  • NEW RESEARCH DEVELOPMENTS
  • TABLE 5 COMPOUNDS IN CLINICAL DEVELOPMENT FOR HEAD AND NECK CANCER
    • LYMPHOSEEK
    • REOLYSIN
    • MULTIKINE
  • MARKET
  • TABLE 6 GLOBAL AND U.S. MOUTH AND LARYNX CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 7 MOUTH AND LARYNX CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 8 CANCER OF MOUTH AND LARYNX FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

CHAPTER 6 CANCER OF THE ESOPHAGUS

  • CAUSE, FREQUENCY AND COURSE
  • DIAGNOSIS
  • TREATMENT
  • NEW RESEARCH DEVELOPMENTS
    • GENETICS
    • SCREENING AND PREVENTION
    • SURGERY
    • CHEMOTHERAPY
    • TARGETED DRUGS
    • TABLE 9 COMPOUNDS IN CLINICAL DEVELOPMENT FOR ESOPHAGEAL CANCER
  • MARKET
  • TABLE 10 GLOBAL AND U.S. ESOPHAGEAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 11 ESOPHAGEAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 12 ESOPHAGEAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

CHAPTER 7 LIVER CANCER

  • CAUSE, FREQUENCY AND COURSE
  • DIAGNOSIS
  • TREATMENT
  • OTHER PRIMARY LIVER CANCERS
  • METASTASES
  • NEW RESEARCH DEVELOPMENTS
    • VIRUS THERAPY
    • TABLE 13 LIVER CANCER: NEW DEVELOPMENTS IN RESEARCH
  • MARKET
  • TABLE 14 GLOBAL AND U.S. LIVER CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 15 LIVER CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 16 LIVER CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

CHAPTER 8 RENAL CANCER

  • CAUSE, FREQUENCY AND COURSE
  • DIAGNOSIS
  • TREATMENT
  • NEW RESEARCH DEVELOPMENTS
    • GENETICS
    • NEW APPROACHES TO LOCAL TREATMENT
    • TARGETED THERAPIES
    • IMMUNOTHERAPY
    • VACCINES
    • BONE MARROW OR STEM CELL TRANSPLANT
    • TABLE 17 RENAL CANCER: NEW RESEARCH DEVELOPMENTS
  • MARKET
  • TABLE 18 GLOBAL AND U.S. RENAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 19 RENAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 20 RENAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

CHAPTER 9 CANCER OF THE PANCREAS

  • CAUSE, FREQUENCY AND COURSE
  • DIAGNOSIS
  • TREATMENT
  • NEW RESEARCH DEVELOPMENTS
  • TABLE 21 PANCREATIC CANCER: NEW RESEARCH DEVELOPMENTS
  • MARKET
  • TABLE 22 GLOBAL AND U.S. PANCREATIC CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 23 PANCREATIC CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 24 PANCREATIC CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

CHAPTER 10 CANCER OF THE CERVIX

  • CAUSE, FREQUENCY AND COURSE
  • DIAGNOSIS
  • TREATMENT
    • PREVENTION: VACCINES
    • TREATMENT
      • Cisplatin
      • Ifosfamide (Ifex)
      • Fluorouracil (Adrucil)
      • Paclitaxel (Taxol)
      • Topotecan (Hycamtin)
      • Docetaxel
      • Gemcitabine
      • Vaccines: Inactivated, Viral
      • Human Papillomavirus Vaccine, Quadrivalent (Gardasil)
      • Human Papillomavirus Vaccine, Bivalent (Cervarix)
      • Targeted Drug Therapy
  • NEW RESEARCH DEVELOPMENTS
    • IXEMPRA
    • ISA101 VACCINE
    • VELIPARIB
    • OLAPARIB
      • Avastin
      • TABLE 25 NEW RESEARCH DEVELOPMENTS IN CERVICAL CANCER
  • MARKET
  • TABLE 26 GLOBAL AND U.S. CERVICAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 27 CERVICAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 28 CERVICAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

CHAPTER 11 OVARIAN CANCER

  • CAUSE, FREQUENCY AND COURSE
  • DIAGNOSIS
  • TREATMENT
    • PACLITAXEL
    • CARBOPLATIN
    • DOXIL
    • TAXOTERE/DOCETAXEL
    • CISPLATIN
    • GEMZAR
    • HYCAMTIN
    • NAVELBINE
    • CARBOPLATIN
  • OVARIAN CANCER SCREENING
    • CA125 BLOOD TEST
    • TRANSVAGINAL ULTRASOUND
  • NEW DEVELOPMENTS IN TREATMENT
    • RISK FACTORS AND CAUSES
    • PREVENTION
    • DIAGNOSIS
    • TREATMENT
      • Chemotherapy
      • Targeted Therapy
      • Immunotherapy
      • ASCO 2013
      • Asco 2014
      • Other Developments
      • TABLE 29 NEW DEVELOPMENTS IN OVARIAN CANCER RESEARCH
  • MARKET
  • TABLE 30 GLOBAL AND U.S. OVARIAN CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 31 OVARIAN CANCER MARKET, FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 32 OVARIAN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

CHAPTER 12 TUMOR MARKERS

  • SCREENING AND EARLY DETECTION
  • DIAGNOSING CANCER
  • MONITORING
    • LOOKING FOR RECURRENCE
      • Tumor Markers Found in Blood or Urine
      • Alpha-fetoprotein (AFP)
      • BCR-ABL
      • Beta-2-microglobulin (B2M)
      • Beta-HCG
      • Bladder Tumor Antigen (BTA)
      • CA 15-3
      • CA 19-9
      • CA 27-29
      • CA 125
      • Calcitonin
      • Carcinoembryonic Antigen (CEA)
      • Chromogranin A
      • HE-4
      • Human Chorionic Gonadotropin (HCG)
      • Immunoglobulins
      • Free Light Chains
      • Inhibin
      • Neuron-specific Enolase (NSE)
      • NMP22
      • Prostate-specific Antigen (PSA)
      • Prostatic Acid Phosphatase (PAP)
      • S-100
      • Soluble Mesothelin-Related Peptides (SMRP)
      • Thyroglobulin
  • TUMOR MARKERS FOUND ON THE CANCER ITSELF
    • ANAPLASTIC LYMPHOMA KINASE (ALK)
    • BRAF
    • EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
    • HER2 (OR HER2/NEU, ERBB-2, OR EGFR2)
    • HORMONE RECEPTORS
    • KRAS
    • S-100
  • NEW DIRECTIONS IN TUMOR MARKER RESEARCH
    • GENOMICS
    • PROTEOMICS

CHAPTER 13 COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ADVAXIS
  • AMGEN
  • APP PHARMACEUTICALS
  • ASTRAZENECA
  • BAYER
  • BIONUMERIK PHARMACEUTICALS
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CELL THERAPEUTICS INC.
  • CHUGAI PHARMACEUTICAL
  • CLOVIS ONCOLOGY
  • DENDREON CORP.
  • DIGENE CORP.
  • EISAI INC.
  • ELI LILLY AND COMPANY
  • ENDOCYTE
  • FUJIREBIO DIAGNOSTICS
  • GE HEALTHCARE
  • GENENTECH
  • GLAXOSMITHKLINE
  • ISA PHARMACEUTICALS
  • JOHNSON & JOHNSON
  • LPATH
  • MERCK
  • MYRIAD GENETICS
  • NOVOCURE
  • OASMIA PHARMACEUTICAL
  • ONCOLYTICS
  • OXIGENE
  • PFIZER
  • PROVISTA DIAGNOSTICS
  • QIAGEN
  • QUEST DIAGNOSTICS
  • RADIENT PHARMACEUTICALS
  • ROCHE DIAGNOSTICS
  • SANOFI
  • TELIK INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • ZILICO

CHAPTER 14 APPENDIX 1: GLOSSARY

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR "SILENT" CANCERS, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 COMPOUNDS IN CLINICAL DEVELOPMENT FOR BRAIN CANCER
  • TABLE 2 GLOBAL AND U.S. BRAIN CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 3 BRAIN CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 4 BRAIN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
  • TABLE 5 COMPOUNDS IN CLINICAL DEVELOPMENT FOR HEAD AND NECK CANCER
  • TABLE 6 GLOBAL AND U.S. MOUTH AND LARYNX CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 7 MOUTH AND LARYNX CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 8 CANCER OF MOUTH AND LARYNX FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
  • TABLE 9 COMPOUNDS IN CLINICAL DEVELOPMENT FOR ESOPHAGEAL CANCER
  • TABLE 10 GLOBAL AND U.S. ESOPHAGEAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 11 ESOPHAGEAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 12 ESOPHAGEAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
  • TABLE 13 LIVER CANCER: NEW DEVELOPMENTS IN RESEARCH
  • TABLE 14 GLOBAL AND U.S. LIVER CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 15 LIVER CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 16 LIVER CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
  • TABLE 17 RENAL CANCER: NEW RESEARCH DEVELOPMENTS
  • TABLE 18 GLOBAL AND U.S. RENAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 19 RENAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 20 RENAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
  • TABLE 21 PANCREATIC CANCER: NEW RESEARCH DEVELOPMENTS
  • TABLE 22 GLOBAL AND U.S. PANCREATIC CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 23 PANCREATIC CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 24 PANCREATIC CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
  • TABLE 25 NEW RESEARCH DEVELOPMENTS IN CERVICAL CANCER
  • TABLE 26 GLOBAL AND U.S. CERVICAL CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 27 CERVICAL CANCER MARKET FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 28 CERVICAL CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)
  • TABLE 29 NEW DEVELOPMENTS IN OVARIAN CANCER RESEARCH
  • TABLE 30 GLOBAL AND U.S. OVARIAN CANCER MARKET, THROUGH 2019 ($ MILLIONS)
  • TABLE 31 OVARIAN CANCER MARKET, FOR MAJOR EUROPEAN COUNTRIES, THROUGH 2019 ($ MILLIONS)
  • TABLE 32 OVARIAN CANCER MARKET FOR JAPAN AND REST OF WORLD, THROUGH 2019 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET SHARE FOR (%)
Back to Top